Jennifer Taylor, NP
Gerontology · Abingdon, VANPI 1487620274
Payments from drug & device makers
Across 519 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- AstraZeneca$786
- Abbott$652
- Medtronic$546
- Dexcom, Inc.$480
- plus $3K from 29 others
What the payments were for
- Food & beverage$9,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 100 | $1,729 |
| Lilly USA, LLC | 103 | $1,580 |
| AstraZeneca | 51 | $786 |
| Abbott | 39 | $652 |
| Medtronic | 25 | $546 |
| Dexcom, Inc. | 28 | $480 |
| Boehringer Ingelheim | 23 | $426 |
| Bayer | 19 | $337 |
| Corcept Therapeutics | 16 | $319 |
| Amgen(2 entities) | 18 | $286 |
| Insulet Corporation | 15 | $279 |
| Novartis | 12 | $246 |
| Esperion Therapeutics, Inc. | 9 | $204 |
| Sanofi-aventis U.S. LLC | 12 | $198 |
| AbbVie | 7 | $134 |
| Tandem Diabetes Care, Inc. | 4 | $106 |
| Xeris Pharmaceuticals, Inc. | 6 | $102 |
| Recordati_rare_diseases_inc. | 5 | $92 |
| Antares Pharma, Inc. | 5 | $83 |
| Organogenesis Inc. | 3 | $63 |
| Sequel Med Tech, LLC | 2 | $60 |
| Madrigal Pharmaceuticals | 1 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| Mannkind Corporation | 1 | $31 |
| Halozyme Inc | 2 | $30 |
| Reapplix Inc. | 1 | $29 |
| BD | 1 | $23 |
| Clarus Therapeutics Inc. | 2 | $23 |
| BETA Bionics, Inc. | 1 | $18 |
| Solventum Corporation | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Advanced Oxygen Therapy Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
| Zealand Pharma US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$125
How this compares
$9,014 in reported general payments places this provider in the 95th percentile of 130 gerontology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 193 | $217,986 |
| MounjaroTirzepatide | 135 | $152,304 |
| TrulicityDulaglutide | 103 | $130,466 |
| Tresiba Flextouch U-200Insulin Degludec | 111 | $112,912 |
| JardianceEmpagliflozin | 95 | $78,389 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 26 | $74,988 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $49,329 |
| Novolog FlexpenInsulin Aspart | 125 | $41,847 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 259 | $34,844 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $34,362 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $32,116 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 24 | $32,050 |
| FarxigaDapagliflozin Propanediol | 40 | $31,192 |
| NovologInsulin Aspart | 95 | $30,874 |
| Humalog Kwikpen U-100Insulin Lispro | 94 | $24,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $1,580 | $305,260326 claims |
| Novo NordiskOzempic, Novolog | $1,729 | $248,859288 claims |
| Boehringer IngelheimJardiance | $426 | $78,38995 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $198 | $49,102105 claims |
| AstraZenecaFarxiga | $786 | $31,19240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 gerontology providers in Virginia.
Other gerontology in Abingdon
- Lauren FerrisRoanoke$11K
- Catherine RatliffCharlottesville$10K
- Alexander KingCharlottesville$7K
- Margaret HeidenreichChantilly$6K
- Jillian MaurielloRichmond$6K
- Christine HowellNorfolk$6K
- Molly McCrackenRichmond$5K
- Meredith OverstreetManassas$5K
- Danielle JenningsRichmond$5K
- Martha Alejandro-BirdWilliamsburg$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.